Britain approved the first two -price new crown vaccine for primitive strains and Omircong variants

Recently, the world's first two -valent (referring to the prevention of two virus variants) was approved in the UK. This vaccine developed by American biotechnology company Moderna will also have the effect on the primitive strains and Omiroko variants at the same time. During the popularity of the new crown, Modner was known to the public with the MRNA vaccine technology.

The British Pharmaceutical and Health Products Administration (MHRA) gives a more specific statement: the vaccine can produce a strong immune response to the new crown primitive strain and the Omikonia variant BA.1 Rong's other sub -variants, namely BA.4 and BA.5. The regulatory agency said that the side effects of this vaccine are similar to the original enhanced needle of Modner, usually mild, without serious safety issues.

According to public reports, the British vaccination and immunomotive joint committee (JCVI) said the vaccine will be used for strengthening plans for this fall.

Several groups of data on this two -valent vaccine are worthy of attention: 1. Compared with two -dose original vaccine: A subject who has not been infected with the new crown virus to strengthen the second -price vaccine for one month, the average geometric antibody geometric average drip Degree (GMT) is 8 times higher than those with two primitive vaccines in vaccination. 2. Compared with the enhanced vaccination of the original vaccine: Strengthening the GMT of the second -price vaccine to BA.1 is 1.7 times higher than the original vaccine. 3. Resistance to other mutant plants: For other World Health Organization (WHO), it is listed as "mutant strains that need attention" (VOC). The two -valent vaccine enhanced vaccination -induced antibody level is also significantly higher than the original vaccine.

It is reported that Modner has also submitted the vaccine review to Australia, Canada and the European Union. It is worth noting that the United States has not approved relevant listing applications. The US Food and Drug Administration (FDA) stated that it is more inclined to use vaccines against BA.4/5.

The British move caused heated discussions.

Sony Salzman, a coordinator of the news department of the news department of the US Broadcasting Corporation, said in a talk with the "Start Here" podcast that the new binary vaccine was a "turning point".

"I think these new vaccines will enable us to enter the next stage of major epidemic diseases, just like the flu vaccine every year or each season." Salzman said, "We must predict what the virus will do and design a vaccine for vaccine , To achieve the best resistance effect. "

However, he still emphasized that the new binary vaccine can only be "better match" with the new variants of the virus. In fact, due to the great changes in the virus itself, "it is impossible to get an impeccable vaccine", which makes people avoid any breakthrough infection.

It is understood that the new crown vaccine on the market and the enhanced needle are only for the original new crown virus discovered at the end of 2019, which belongs to the "unit price" vaccine; a new type of binary vaccine that is working hard in the world is to resist the currently largest proportion of the current global popularity. Omik Rongya variant BA.4/5.

Although in order to resist different virus variants more targeted, many different vaccines should be designed, but because the vaccine formulation, testing, authorization, and distribution require a lot of effort. The development of multi -price vaccines can reduce people's burdens and make people more A antibody of different virus variants is almost produced.

"The MRNA vaccine technology platform greatly shortens the new vaccine research and development schedule. The more effective choice of variant antigen and a more economical immunization vaccination plan is the next issue of new crown vaccine research and development." Tell the surging news.

Reference materials:

1. https://abcnews.go.com/heallth/covid-bivalent-daccine-ExpeCTED-s-fall/Story?id=88441908

2. https://theglobalherald.com/news/uk- approves-firs-9-booster-daccine- to-two-variants/

- END -